ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

WSJ BLOG/Health: A.M. Vitals: Texas Board to Vote on Stem-Cell Rules

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.) By Mark Long Here's what's making health news this morning: Texas Eyes Change in Stem-Cell Rules (WSJ): The state's medical board will vote today on rules that would make it easier for physicians to offer treatments using adult stem cells. Bayer Said to Pay $110 Million in Yaz Birth-Control Cases (Bloomberg News): People familiar with the agreements told Bloomberg that the German drug maker will settle about 500 lawsuits claiming the pills caused blood clots. States Seek Curb on Patient Bills for Costly Drugs (New York Times): Lawmakers in at least 20 states have introduced bills to limit the amount patients with diseases that are expensive to treat have to pay out of pocket. Medicare to Settle Hospital Reimbursement Dispute (Los Angeles Times): The Centers for Medicare and Medical Services agreed to settle the dispute with about 2,200 hospitals over an error in reimbursement rates. Sexual Side Effects Added to Merck Drug Labels (Reuters): U.S. health regulators said the labels for a baldness treatment, Propecia, and one for enlarged prostate, Proscar, will note side effects that lasted after use of the drugs ended. Hospitals Drop Plan for Merger (WSJ): St. Anthony Medical Center and Rockford Memorial Hospital in Rockford, Ill., bowed to pressure from the FTC, which said a deal would make a local monopoly. Novartis: MS Pill Gilenya Patient Develops Rare Brain Disease (Dow Jones Newswires): The multiple-sclerosis patient, diagnosed with often-fatal progressive multifocal leukoencephalopathy, had also been previously treated with another MS drug, Novartis said. -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com.

Stock News for Novartis (NVS)
DateTimeHeadline
01/27/201504:42:08Novartis Upbeat Despite Weaker Profit -- Update
01/27/201502:43:04Novartis Posts Fall in Fourth-Quarter Profit
01/22/201510:31:06Novartis 4Q Profit May Drop -- Earnings Preview
01/22/201510:01:33Novartis 4Q 2014 -- Forecast
01/20/201517:13:11Supreme Court Sides With Teva in Patent Case on Copaxone -- 2nd...
01/20/201512:59:54Supreme Court Sides With Teva in Patent Case on Copaxone -- Update
01/20/201511:02:18Supreme Court Sides With Teva in Patent Case on Copaxone
01/19/201507:30:12Novartis Wins European Approval for Skin Remedy Cosentyx
01/19/201506:22:23EUROPE MARKETS: European Stocks Edge Higher, But Oil Shares Underperform
01/15/201511:56:52Swiss Businesses Fear Franc's Strength --Update
01/15/201510:50:32Swiss Businesses Fear Impact of Central Bank's Franc Move
01/08/201503:12:33Novartis Applies for U.S. Approval for Lung Disease Drugs
01/07/201508:30:09Eli Lilly 2015 Outlook Falls Below Expectations
01/06/201511:20:20India Shares Post Biggest Percentage Decline in 16 Months
01/01/201503:21:24Novartis Completes Sale of Animal Health Division to Eli Lilly
12/22/201418:10:28Vanda, Novartis Settle Drug Licensing Dispute
12/22/201417:59:07Vanda, Novartis Settle Licensing Dispute Over Schizophrenia Drug
12/16/201403:22:10Novartis Gets U.S. Approval for Hormonal Disorder Drug
12/12/201418:22:53Novartis: Afinitor Fails to Make a Significant Treatment Difference
12/03/201423:43:31Array BioPharma to Regain Global Rights to Cancer Therapy

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad